Millendo Therapeutics Inc (MLND) Stock Income Statement
USA - NASDAQ:MLND -
1.06
-0.06 (-5.36%)
1.06
0 (0%)
| TTM (2021-3-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2017 (2017-12-31) | 2016 (2016-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | null | null | null | null | null | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | null | null | null | null | null | |||
| Research and Development | null | null | null | null | null | |||
| Selling, General, and Administrative Expenses | null | null | null | null | null | |||
| Operating Income | null | null | null | null | null | |||
| Interest Income/Expense | null | null | null | null | null | |||
| Other Income/Expense | null | null | null | null | null | |||
| Non Recurring Items | null | null | null | null | null | |||
| Income Before Taxes | null | null | null | null | null | |||
| Income Tax | null | null | null | null | null | |||
| Net Income | null | null | null | null | null | |||
| EBITDA | null | undefined | undefined | undefined | undefined | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | null | null | null | null | null | |||
| Non GAAP EPS | -1.7300000000000002 | -1.94 | -3.26 | -20.85 | -36.75 | |||
| Statistics | ||||||||
All data in USD